N4 Pharma (0GO) AI Stock Analysis

N4 Pharma

(Frankfurt:0GO)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Proprietary Nuvec platformNuvec gives N4 Pharma a defined technology platform that can be applied across multiple drug-delivery markets, including vaccines and oncology. If development and external collaboration progress, the platform could support several commercialization paths rather than relying on one single therapeutic product.

Negative Factors

Persistent unprofitabilityDeep and recurring operating and net losses show that the current business is not economically self-sustaining. Margins substantially below zero indicate costs remain far above the revenue base, creating a durable execution challenge until products, partnerships or licensing generate materially larger income.

N4 Pharma (0GO) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 4.79M
Dividend Yield: ―
Average Volume (3M): 1,500
Price to Earnings (P/E): -7.2
Beta (1Y): -31.25
Revenue Growth: -1.23%
EPS Growth: 28.57%
Country: Germany
Employees: 3
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

N4 Pharma Business Overview & Revenue Model

Company Description

Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular...

N4 Pharma Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:0GO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:EAH	59Neutral	GBP 64.71M	29.57	2.55%	―	9.96%	29.72%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:PXS	49Neutral	GBP 18.77M	-80.00	-44.68%	―	-2.14%	0.00%
GB:STX	42Neutral	GBP 60.69M	-7.72	64.57%	―	36.19%	60.75%
GB:CHLL	38Underperform	GBP 888.98K	-0.00	233.76%	―	―	―

* Healthcare Sector Average

Performance Comparison

DE:0GO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:0GO	N4 Pharma	0.03	0.00	0.00%
GB:EAH	Eco Animal Health	95.50	12.50	15.06%
GB:CHLL	Chill Brands Group PLC	1.70	-8.80	-83.81%
GB:HELD	Mountfield Group plc	0.90	-0.05	-5.26%
GB:PXS	Provexis plc	0.80	0.22	37.93%
GB:STX	Shield Therapeutics	5.65	-1.40	-19.86%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

N4 Pharma AI Stock Analysis